World Investment Advisors Purchases New Stake in SELLAS Life Sciences Group, Inc. $SLS

World Investment Advisors acquired a new position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) during the fourth quarter, HoldingsChannel.com reports. The firm acquired 44,123 shares of the company’s stock, valued at approximately $166,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd grew its holdings in SELLAS Life Sciences Group by 408.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 55,129 shares of the company’s stock valued at $208,000 after buying an additional 44,296 shares in the last quarter. Invesco Ltd. raised its holdings in shares of SELLAS Life Sciences Group by 6.2% during the 4th quarter. Invesco Ltd. now owns 53,293 shares of the company’s stock worth $201,000 after acquiring an additional 3,114 shares during the period. Axxcess Wealth Management LLC boosted its position in shares of SELLAS Life Sciences Group by 121.1% during the 4th quarter. Axxcess Wealth Management LLC now owns 35,370 shares of the company’s stock valued at $133,000 after acquiring an additional 19,370 shares during the last quarter. Beacon Pointe Advisors LLC acquired a new position in shares of SELLAS Life Sciences Group during the 4th quarter valued at about $38,000. Finally, XTX Topco Ltd purchased a new stake in shares of SELLAS Life Sciences Group in the fourth quarter valued at about $447,000. Institutional investors and hedge funds own 17.38% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on SLS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Tuesday, April 21st. Maxim Group increased their price target on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, March 12th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, SELLAS Life Sciences Group has a consensus rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Trading Up 17.7%

NASDAQ SLS opened at $12.39 on Friday. The stock has a fifty day simple moving average of $7.14 and a 200-day simple moving average of $5.16. The stock has a market cap of $2.44 billion, a PE ratio of -53.87 and a beta of 2.50. SELLAS Life Sciences Group, Inc. has a twelve month low of $1.39 and a twelve month high of $12.43.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.